Document:

Exhibit
10.71

 

TERMS

for

NONEXCLUSIVE LICENSE AGREEMENT

between

ADVANCED CELL TECHNOLOGY, INC.

and

IMMERGE BlOTHERAPEUTICS, INC.

 

This
Term Sheet is made and entered into this 23rd day of December, 2000 (the “Effective
Date”), by and between Advanced Cell Technology, Inc., a Delaware corporation
with offices located at One Innovation Drive, Worcester, Massachusetts 01605 (“ACT”),
and Immerge BioTherapeutics, Inc., a Delaware corporation having offices
located at Building 75, 3rd Avenue, Charlestown, MA 02129 (“IBT”) (ACT and IBT sometimes
hereinafter referred to as the “parties”). As indicated below, the University
of Massachusetts,  a public institution
of higher education of the Commonwealth of Massachusetts (the “University”),
has agreed to the terms of this Term Sheet.

 

The following terms are the
principal terms to be included in a more comprehensive written Non-Exclusive
License Agreement (“Agreement”) between ACT and IBT, pursuant to which ACT will
nonexclusively license to IBT certain intellectual property that ACT owns or
has licensed with a sublicensable interest, and which will supercede this Term
Sheet. The parties agree to negotiate in good faith toward the execution of the
Agreement. The parties intend, however, to be bound by this Term Sheet, and if
the University of Massachusetts signs this Term Sheet and an Agreement is not
executed sixty (60) days after the signing of this Term Sheet by University of
Massachusetts, this Term Sheet shall continue in full force and effect and
shall constitute the parties’ binding agreement with respect to the subject
matter hereof. The following provisions shall also be in effect pending the
execution of the Agreement.   If the
University of Massachusetts does not sign this Term Sheet, and IBT is awarded
the NIST Grant described in Schedule B attached hereto, then IBT shall still
owe ACT the payments set forth hereunder in the Section entitled NIST Grant
Issue.

 

	
  Patent Rights:

  	
   

  	
  The patent identified on
  Exhibit A attached hereto and all continuations, continuations in-part,
  divisionals, and foreign filings related thereto.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  ACT hereby grants to IBT a
  right of first negotiation to acquire a non-exclusive license to any future
  patents owned by or licensed to ACT that are necessary to produce Licensed
  Products (as defined below) in the Field (as defined below). In the event ACT
  acquires any such patents, ACT shall notify IBT in writing of its acquisition
  of such patent rights. IBT shall then have a period of thirty (30) days to
  notify ACT in writing of its desire to acquire a non-exclusive license to use
  such patent rights to develop, manufacture, use and
  sell Licensed Products in the Field. If IBT so notifies ACT, then IBT and ACT
  shall negotiate in good faith for not more than sixty (60) days to reach
  agreement on the terms of such license. If, by the end of such sixty (60) day
  period IBT and ACT have not reached agreement, ACT shall be free to enter
  into such non-exclusive licenses with third parties, provided that if ACT
  enters into such a non-exclusive license with a third party, ACT agrees that
  it will offer IBT a similar non-exclusive license with financial terms no 

  

 

 

	
   

  	
   

  	
  worse than those set forth
  in the agreement entered into between ACT and such other third party.

  
	
   

  	
   

  	
   

  
	
  License Grant:

  	
   

  	
  A non-exclusive, worldwide,
  royalty-bearing license to develop, make, have made, use, sell and have sold
  products (“Licensed Products”) (products, the making, using or selling of
  which are covered by a valid, issued claim of a patent included in the
  Patent Rights in the country in which the products are made, used or sold) in
  the Field.

  
	
   

  	
   

  	
   

  
	
  Field:

  	
   

  	
  The cloning of swine for
  the sole purpose of developing, producing and selling swine-derived organs
  (but excluding cells (other than associated immune cells required to induce
  tolerance of the organs) and tissues) for transplantation of such organs in
  humans.

  
	
   

  	
   

  	
   

  
	
  Right of First Negotiation

  	
   

  	
  ACT hereby grants to IBT a
  right of first negotiation to acquire a non-exclusive or exclusive license
  under the Patent Rights to develop, manufacture, use and sell products in the
  field of the cloning of swine for the sole purpose of developing, producing
  and selling swine-derived tissues or cells for transplantation of such
  tissues or cells in humans as follows. ACT shall notify IBT in writing of its
  intention to enter into negotiations for such a
  license with a third party. IBT shall then have a period of thirty (30) days
  to notify ACT in writing of its willingness to enter into such a
  non-exclusive or exclusive license. If IBT so notifies ACT, then IBT and ACT
  shall negotiate in good faith for not more than sixty (60) days to reach
  agreement on the terms of the license. If, by the end of such sixty (60) day
  period, IBT and ACT have not reached agreement. (1) ACT shall be free to
  enter such an exclusive license with a third party but only on terms more
  favorable to ACT than those terms firmly offered by IBT, and (2) ACT shall be
  free to enter into such non-exclusive licenses with third parties, provided
  that if ACT enters into such a non-exclusive license with a third party, ACT
  agrees that it will offer IBT a similar non-exclusive license with financial
  terms no worse than those set forth in the agreement entered into between ACT
  and such other third party.

  
	
   

  	
   

  	
   

  
	
  Sublicenses:

  	
   

  	
  IBT shall not have the
  right to grant sublicenses. However, ACT agrees that the license “to have
  made” or “to have sold” means that IBT may contract with third parties to
  develop, manufacture or sell Licensed Products on behalf of
  IBT.

  
	
   

  	
   

  	
   

  
	
  License Term:

  	
   

  	
  Until expiration of the
  last-to-expire patent issued under the Patent Rights.

  

 

2

 

	
  Financial Terms:

  	
   

  	
  IBT shall pay to ACT for
  the license the following:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  An initial license fee of
  $500,000 due and payable as follows: (1) IBT shall pay to ACT $250,000 thirty
  (30) days following the signing of this term sheet by University of
  Massachusetts (or upon the execution of the Agreement, if earlier) such date
  to be referred to as the Agreement Effective Date”; and (2) IBT shall pay to
  ACT $250,000 on or before the first anniversary of the Agreement Effective
  Date, provided that if the NIST grant described in Schedule B attached hereto
  (the “NIST grant”) has not been awarded to IBT or it’s affiliated companies,
  as evidenced by the written records of IBT, said second $250,000 fee will not
  be due. The license fee shall be
  non-refundable and is not creditable against any other payments due to ACT
  hereunder or under the Agreement.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  An
  earned royalty, due and payable on a calendar quarterly basis, of 3% on net
  sales of Licensed Products by IBT or any party that sells the Licensed
  Products on behalf of IBT, provided, however, that in the event that IBT is
  legally required to make royalty payments to one or more third parties in
  order to make, use or sell Licensed Products, IBT’s royalty payment shall be decreased by one-half of one
  percent (0.5%) for each one percent (1%) of actual royalty payments made to
  third parties under such required licenses. In no case, however, shall the
  annual royalty due to ACT be less than 1.0% of net sales.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  In no event shall more
  than one royalty be due for any Licensed Product sold by IBT or a party on
  its behalf,

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  For purposes of this Term
  Sheet or the Agreement, as applicable, “Net Sales” shall mean the amount
  billed or invoiced by IBT (or any third party that sells the Licensed
  Products on behalf of IBT) for the sale of Licensed Products, less (i)
  discounts allowed; (ii) sales taxes, tariff duties, use and other taxes
  directly imposed with reference to particular sales; (iii) amounts repaid or
  credited by reason of rejection, return of goods, retroactive price reduction
  or bad debt; (iv) freight, postage and insurance invoiced to the customer;
  (v) third party rebates to the extent actually allowed; and (vi) liabilities
  incurred resulting from any governmental (or agency thereof) mandated rebate
  program, whether federal, state, municipal or local.

  
	
   

  	
   

  	
   

  
	
  Royalty Reports, Payments,
  Records and Audits

  	
   

  	
  IBT shall submit a report
  to ACT quarterly within 45 days after the end of each calendar quarter during
  the term of this Term Sheet or the Agreement, as applicable, stating in each
  such report the aggregate sales and payments with respect to Licensed
  Products during the preceding calendar quarter and the royalty as provided
  herein. Such reports shall also include a statement of

  

 

3

 

	
   

  	
   

  	
  any credits claimed during
  the preceding calendar quarter. The payment of royalty amounts shall be made
  concurrently with such reports. IBT shall keep full, complete, true and
  accurate books of account containing all particulars relating to the
  manufacture and sales with respect to Licensed Products, and any allowed
  credits, which may be necessary to ascertain and verify the royalties payable
  to ACT. Said books and accounts shall be kept at IBT’s principal place of
  business. At the request of ACT, but not more than once in each calendar year
  and provided ACT provides IBT with at least ten (10) days prior written
  notice, IBT shall permit an independent certified public accountant, selected
  by ACT, to have access, during regular business hours of IBT, to such records
  to determine, for any calendar quarter commencing not more than two years
  prior to the date of such request, the completeness and accuracy of such
  books and records, and the accuracy of reports submitted to ACT and/or
  payments made to ACT. If any such inspection discloses an error in any
  royalty payment, IBT shall pay to ACT, within thirty (30) days of the
  discovery of the error, (a) all deficiencies in royalty payments, (b)
  interest on such deficiencies from the date such royalty payment was due
  until the date paid at the rate equal to one and one-half percent (1 l/2%)
  per month, and (c) if such error is in excess of ten percent (10%) of any
  royalty payment, the cost of the audit. In all other cases, the costs of the
  audit shall be paid for by ACT. All information disclosed pursuant to an
  audit shall be treated as confidential information and shall not be disclosed
  to any third party or used for any purpose other than to determine the
  correctness of the payment

  
	
   

  	
   

  	
   

  
	
  NIST Grant Issue

  	
   

  	
  If the University of
  Massachusetts does not sign this Term Sheet and IBT is awarded the NIST
  grant, IBT shall pay ACT $250,000 within thirty (30) days of being awarded
  the NIST grant and an additional $250,000 upon the one year anniversary of
  the date IBT is awarded the NIST grant. In such situation, ACT agrees that it
  will use best efforts to obtain the consent of University of Massachusetts to
  a license agreement that contains terms as similar to the terms contained in
  this Term Sheet as possible.

  
	
   

  	
   

  	
   

  
	
  Representations and
  Warranties

  	
   

  	
  IBT and ACT represent and
  warrant that they have full corporate power and authority to enter into this
  Term Sheet, that this Term Sheet constitutes the binding legal obligation of
  IBT and ACT and that execution and performance of this Term Sheet or the
  Agreement, as applicable, by IBT and ACT will not violate, contravene or
  conflict with any other agreement to which IBT or ACT is a party or by which
  it is bound or with any law, rule or regulation applicable to IBT or ACT.

  
	
   

  	
   

  	
   

  
	
  Most
  Favored Licensor:

  	
   

  	
  IBT represents and
  warrants that it and its Affiliated Companies (a corporation, company,
  partnership, joint venture or other entity which controls, is controlled
  by or is under common

  

 

4

 

	
   

  	
   

  	
  control with another
  entity) has not entered into any license or other agreement with Infigen or
  any of its Affiliated
  Companies, which is still ongoing and will not, during the term of this Term
  Sheet or the Agreement enter into any license or other agreement with Infigen
  or any of its Affiliated Companies that grants IBT rights under the current
  patents or proprietary technology
  of Infigen directed to nuclear transfer to manufacture or sell organs derived
  from nuclear transfer produced swine for transplantation in humans on terms
  that are more favorable on the whole to Infigen or any of its Affiliated
  Companies) than the terms set forth in this Term Sheet. If IBT or any of its
  Affiliated Companies enter into any such license or other agreement with
  Infigen or any of its Affiliated Companies on terms that are more favorable
  on the whole to Infigen than the terms set forth in this Term Sheet, then IBT
  will (a) promptly notify ACT of such license, and (b) extend to ACT the terms
  of the noticed license, effective as of the date (or dates) on which they
  became effective in respect to the noticed license. Such extension of the
  terms of the noticed license shall be effective, however, only if ACT shall,
  within sixty (60) days of receipt of the notice referred to in provision (a)
  above, advise IBT that it accepts all terms of the noticed license.

  
	
   

  	
   

  	
   

  
	
  Obligations Relating to
  Commercialization:

  	
   

  	
  IBT shall use its
  commercially reasonable and diligent efforts to bring one or more Licensed
  Products to market.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  IBT shall maintain
  complete and accurate records of Licensed Products that are made, used, sold
  or performed by IBT under this Agreement. 
  Not later than May 1st of each year beginning in 2001, IBT shall furnish ACT with a summary
  report on the progress of its efforts during the prior year to develop and
  commercialize Licensed Products, including without limitation research and
  development efforts, efforts to obtain regulatory approval, marketing efforts
  (including Licensed Products made, used, or sold) and sales figures, provided
  that such reports shall be deemed confidential information subject to the
  confidentiality provisions of the Agreement. If this Term Sheet becomes the Agreement,
  then ACT agrees that it will not disclose to any third party (except under
  confidentiality to the University of Massachusetts, to the extent required by
  the Exclusive License Agreement dated as of April 16, 1996 between ACT and
  the University of Massachusetts, as amended) or use for any purpose, other
  than to determine diligence, the information provided to it in such reports
  except as required by law. This obligation of confidentiality shall not apply
  to information that is in the public domain through no act of ACT.

  

 

5

 

	
  Patents:

  	
   

  	
  ACT will be responsible for the
  filing, prosecution, maintenance and enforcement of the patents and patent
  applications included in the Patent Rights. ACT will keep IBT informed on a
  regular basis of the status of the Patent Rights.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  The parties agree to
  notify each other in writing of any actual or threatened infringement by a
  third party of an issued patent included in the Patent Rights or of any claim
  of invalidity, unenforceability, or non-infringement of an issued patent
  included in the Patent Rights. ACT shall have the sole responsibility to
  prosecute or defend such claims, as applicable. IBT shall if requested
  provide reasonable assistance to ACT, at ACT’s expense, in connection with
  the prosecution or defense of such claims.

  
	
   

  	
   

  	
   

  
	
  Indemnity and Insurance:

  	
   

  	
  IBT will indemnify,
  defend, and hold harmless ACT and its officers, directors, etc. and their
  respective successors, heirs and assigns against any liability, damage, loss,
  expense (including reasonable attorneys fees and expenses of litigation),
  etc. incurred by or imposed upon any of the indemnified parties in connection
  with any third party claims, suits, actions, demands, judgments, etc.
  concerning any product, process, or service that is made, used, or sold
  pursuant to any right or license granted under the Agreement except to the
  extent due to the negligence or willful misconduct of any of such indemnified
  parties or due to patent infringement on the part of ACT or such indemnified
  parties and provided that ACT shall notify IBT promptly in writing of any
  such claim and IBT shall control the defense and/or settlement of any such
  claim.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  IBT agrees to maintain
  insurance or self-insurance that is reasonably adequate to fulfill any
  potential obligation to the indemnified parties, subject to agreed upon
  specified minimum levels of insurance.

  
	
   

  	
   

  	
   

  
	
  Assignment:

  	
   

  	
  This Term Sheet, or the
  Agreement, as applicable, shall not be assignable to another party without
  the prior written consent of the other party, which shall not be unreasonably
  withheld, but may be assigned by ACT or IBT, without consent of the other
  party to an Affiliated Company or to another party in the case of the sale or
  transfer to such party of all, or substantially all, of the assets of IBT or
  ACT.

  
	
   

  	
   

  	
   

  
	
  Termination:

  	
   

  	
  Either party may terminate
  this Term Sheet or the Agreement, as applicable, for material breach by the
  other party open written notice and a 60 day cure period. IBT shall have the
  right to terminate this Term Sheet or the Agreement, as applicable, for any
  reason upon sixty (60) days written notice to ACT; provided, however, that in
  the event IBT so terminates this Term Sheet or the Agreement, as applicable,
  prior to the one year anniversary

  

 

6

 

	
   

  	
   

  	
  of the Agreement Effective
  Date, IBT agrees that it shall, despite such termination, pay to ACT $500,000
  on the schedule outlined under Financial Terms or NIST Grant Issue, whichever
  occurs first.

  

 

The parties further agree
that the final form of the Non-Exclusive License Agreement (the “Agreement”),
and any sublicense entered into pursuant to the rights of first negotiation
described herein, shall be subject to the approval of the University of
Massachusetts, with the understanding, however, that if the Agreement is not
entered into, University of Massachusetts will be bound by the terms of this
Term Sheet.

 

	
  Notices:

  	
   

  	
  All notices pertaining to
  this Term Sheet shall be in writing and sent certified mail, return receipt
  requested, or by nationally recognized overnight carrier to the parties at
  the following addresses or such other addresses as such party furnishes to
  the other party in accordance with this paragraph. Such notice shall be
  effective upon receipt.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  For ACT: 

  	
  Michael D. West, Ph.D.

  
	
   

  	
   

  	
   

  	
  Advanced Cell Technology,
  Inc.

  
	
   

  	
   

  	
   

  	
  One Innovation Drive

  
	
   

  	
   

  	
   

  	
  Worcester, MA 01605

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  For IBT: 

  	
  Julia Greenstein, Ph.D.

  
	
   

  	
   

  	
   

  	
  Immerge BioTherapeutics,
  Inc.

  
	
   

  	
   

  	
   

  	
  Building 75

  
	
   

  	
   

  	
   

  	
  Third Avenue

  
	
   

  	
   

  	
   

  	
  Charlestown, MA 02129

  

 

IN WITNESS WHEREOF, the parties have caused
this Term Sheet to be executed by their duly authorized representatives as of
the Effective Date.

 

	
  ADVANCED CELL TECHNOLOGY,
  INC.

  	
  IMMERGE BIOTHERAPEUTICS,
  INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
  By: 

  	
  /s/ Michael West

  	
  12-23-00

  	
   

  	
  By:

  	
  /s/ Julia Greenstein

  	
  12/23/00

  	
   

  
	
  Printed Name:

  	
  MICHAEL WEST

  	
   

  	
  Printed Name:

  	
  Julia Greenstein

  	
   

  
	
  Its:

  	
  President

  	
   

  	
  Its:

  	
  President and CEO

  	
   

  
											

 

7Exhibit
10.72

 

WITHDRAWAL, TERMINATION, ASSIGNMENT

AND ASSUMPTION AGREEMENT

 

THIS
WITHDRAWAL, TERMINATION,
ASSIGNMENT AND ASSUMPTION AGREEMENT
(“Agreement”) is made effective as of the 14th day of March, 2001 by and
between BioTransplant Incorporated, a Delaware corporation with offices located
at Building 75, Third Avenue, Charlestown, MA 02129 (“BTI”), Immerge Biotherapeutics,
Inc. a Delaware corporation with offices at Building 75, Third Avenue,
Charlestown, MA 02129 (“Immerge”), Infigen, Inc., a Delaware corporation with
offices at 1825 Infinity Drive,
DeForest, WI 53532 (“Infigen”) and Advanced Cell Technology, a Delaware
corporation with offices at One Innovation Drive, Worcester, MA 01605 (“ACT”).

 

WHEREAS,
BTI and ACT were selected for participation in the Advanced Cell Technology
Program administered by the National Institute of Standards and Technology (“NIST”)
as a joint venture to conduct certain specified research; and

 

WHEREAS,
in connection with such selection, BTI and ACT entered into a Joint Venture
Agreement (the “ACT Joint Venture”) for the purpose of participating in the
Advanced Cell Technology Program; and

 

WHEREAS,
the ACT Joint Venture and NIST entered into a certain NIST Cooperative
Agreement, defining the terms and conditions of NIST’s participation in and
funding of the specified research; and

 

WHEREAS,
subsequent to entering into the ACT Joint Venture and the NIST Cooperative
Agreement, BTI and ACT agreed that ACT would withdraw from the project and that
BTI and Novartis Pharma A.G. (“Novartis”) would, through joint formation of Immerge,
enter into a new joint venture arrangement with Infigen (the “Immerge/Infigen
Revised Joint Venture”) for the purposes of performing under the NIST
Cooperative Agreement; and

 

WHEREAS,
the parties are desirous of amending and assigning the documentation to reflect
and effectuate the foregoing;

 

NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, the parties agree as follows.

 

1.             Pursuant to the provisions of the
ACT Joint Venture, ACT hereby withdraws as a party to the ACT Joint Venture.
The ACT Joint Venture is therefore terminated in all
respects effective as of March 14, 2001, and neither BTI nor ACT has any outstanding or further obligations to the other or to any
third parties thereunder.

 

2.             ACT consents to BTI’s formation of
and participation in Immerge for the purpose of performing with Infigen,
pursuant to the Immerge/Infigen Revised Joint Venture, under the NIST
Cooperative Agreement. Subject to NIST approval and amendment of the NIST
Cooperative Agreement, ACT hereby assigns and releases to the

 

 

Immerge/Infigen Revised
Joint Venture any right, title or interest ACT may have in or under the NIST
Cooperative Agreement, it being the intent of the parties that Immerge and Infigen
(the Immerge/Infigen Revised Joint Venture) be substituted for BTI and ACT (the
ACT Joint Venture) under an amended NIST Cooperative Agreement.

 

3.             The parties agree that ACT is
released from any and all obligations under the NIST Cooperative Agreement.

 

4.             BTI and Immerge, jointly and
severally, hereby agree to defend, indemnify and hold harmless ACT, its
directors, officers, employees, agents, successors and assigns (the “Indemnitees”),
from and against any and all liabilities, damages, costs, losses and expenses,
including reasonable attorneys’ fees, arising out of any third party claims
(including without limitation by Novartis or NIST) made in connection with or
in relation to the ACT Joint Venture or the termination of the ACT Joint
Venture, the substitution of Immerge for the ACT Joint Venture under the NIST
Cooperation Agreement, or the NIST Cooperative Agreement and/or any research,
inventions, work or by products arising thereunder, excepting only claims that
result from the gross negligence or willful misconduct of any of the
Indemnitees. Any indemnification obligations set forth in this Agreement shall
be subject to the following conditions: (i) the indemnified party shall notify
the indemnifying party in writing promptly upon learning of any claim or suit
for which indemnification is sought; (ii) the indemnifying party shall have
control of the defense or settlement of such claim or suit, provided that
the indemnified party shall have the right (but not the obligation) to
participate in such defense or settlement with counsel at its selection and at
its sole expense; and (iii) the indemnified party shall reasonably cooperate
with the defense, at the indemnifying party’s expense.

 

5.             The parties hereto agree and
acknowledge that amending the NIST Cooperative Agreement to substitute Immerge
and Infigen (the Immerge/Infigen Revised Joint Venture) for BTI and ACT (the
ACT Joint Venture) requires the approval and consent of NIST.

 

6.             Nothing in this Agreement is
intended to affect or supersede those certain “Terms for NonExclusive License”
entered into by and between ACT and Immerge on or about December 23, 2000, and
such Terms and all provisions thereof, and any amendments thereto, remain in
full force and effect.

 

[THE REMAINDER OF THIS PAGE HAS BEEN
INTENTIONALLY LEFT BLANK]

 

2

 

IN
WITNESS WHEREOF, the parties, through their respective duly authorized
representatives, have executed this Agreement effective as of the date first
written above.

 

	
   

  	
  BIOTRANSPLANT INCORPORATED

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ [ILLEGIBLE]

  
	
   

  	
  Printed
  Name:

  	
   [ILLEGIBLE]

  
	
   

  	
  Title:

  	
  VP Finance & Treasurer

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  IMMERGE BIOTHERAPEUTICS,
  INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Julia Greenstein

  
	
   

  	
  Printed Name:

  	
  Julia Greenstein

  
	
   

  	
  Title:

  	
  President and CEO

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  ADVANCED CELL TECHNOLOGY

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Robert Lanza

  
	
   

  	
  Printed Name:

  	
  Robert Lanza

  
	
   

  	
  Title:

  	
  Vice President

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  INFIGEN, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Walter Simson

  
	
   

  	
  Printed Name:

  	
  Walter Simson

  
	
   

  	
  Title:

  	
  CEO

  
					

 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}]]